The Clinicopathologic Significance of the Loss of BAF250a ( ARID1A) Expression in Endometrial Carcinoma
The Clinicopathologic Significance of the Loss of BAF250a ( ARID1A) Expression in Endometrial Carcinoma
复制标题
DOI：
10.1097/igc.0000000000000092
复制
发表时间：
2014-03-01
影响因子：
4.8
通讯作者：
Shan, Bao-en
中科院分区：
文献类型：
--
作者：
Zhang, Zheng-mao;Xiao, Shuang;Shan, Bao-en
目的ARID1A基因是编码BAF 250 a蛋白的抑癌基因。最近的研究表明，ARID1A表达的损失在几种类型的肿瘤。目的探讨BAF 250 a在子宫内膜癌中的临床及病理意义。方法检测BAF 250 a在子宫内膜癌中的表达及其与p53、雌激素受体、孕激素受体、糖皮质激素受体、低氧诱导因子-1、BAF 250和血管内皮生长因子在正常子宫内膜和各种恶性子宫内膜组织中的表达。与正常子宫内膜组织相比，25%的子宫内膜癌组织中BAF 250 a表达缺失，而正常子宫内膜组织、复杂性子宫内膜增生和不典型子宫内膜增生组织中BAF 250 a表达缺失。BAF 250 a在子宫内膜癌中的表达缺失率较高，尤其是子宫内膜样癌和子宫透明细胞癌。BAF 250 a在低分化子宫内膜腺癌中的表达与雌激素受体呈正相关，与p53呈负相关。此外，BAF 250 a的表达与子宫内膜癌的分化状态，但不相关的临床分期，肌层浸润深度，淋巴结转移，和患者的总生存率与endometrial carcinoma. Conclusions我们的数据表明，BAF 250 a的丢失是经常发现在高级别类胶质细胞癌和透明细胞癌，而不是在其他类型的子宫内膜癌。BAF 250 a表达的缺失对子宫内膜癌没有预后价值。
Objective AT-rich interactive domain 1A (ARID1A) is a tumor suppressor gene that encodes the BAF250a protein. Recent studies have shown the loss of ARID1A expression in several types of tumors. We aimed to investigate the clinical and pathologic role of BAF250a in endometrial carcinoma.Methods We examined the expression of BAF250a and its correlation with the expression of p53, estrogen receptor, progesterone receptor, glucocorticoid receptor, hypoxiainduciblefactor-1, and vascular endothelial growth factor in normal and various malignant endometrial tissues.Results The expression of BAF250 was significantly down-regulated in endometrial carcinoma when compared with normal endometrial tissues. The loss of BAF250a expression was found in 25% of endometrial carcinoma samples but not in normal endometrial tissues, complex endometrial hyperplasia, and atypical endometrial hyperplasia samples. Subtypes of endometrial carcinoma, especially uterine endometrioid carcinoma and uterine clear cell carcinoma, had higher frequency of loss of BAF250a expression. In addition, the expression of BAF250a was positively correlated with estrogen receptor and negatively correlated with p53 in poorly differentiated endometrial adenocarcinoma. Moreover, the expression of BAF250a was significantly associated with the differentiation status of endometrial carcinoma but not associated with clinical stage, the depth of myometrial invasion, lymph node metastasis, and overall survival of patients with endometrial carcinoma.Conclusions Our data showed that loss of BAF250a is frequently found in high-grade endometrioid and clear cell carcinomas but not in other types of endometrial carcinoma. The loss of BAF250a expression does not have prognostic value for endometrial carcinoma.